Compare · LUCD vs MDLN
LUCD vs MDLN
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.74B, about 383.3x LUCD ($121.9M).
- Over the past year, LUCD is down 48.9% and MDLN is down 13.0% - MDLN leads by 35.9 points.
- MDLN has been more active in the news (4 items in the past 4 weeks vs 2 for LUCD).
- MDLN has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- Medline Inc.
- Price
- $0.63+3.99%
- $35.45-0.31%
- Market cap
- $121.9M
- $46.74B
- 1M return
- -30.22%
- +2.16%
- 1Y return
- -48.91%
- -13.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 2
- 4
- Recent ratings
- 6
- 25
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest LUCD
- Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
- PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
- Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Latest MDLN
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)